Market Size of Antibody Drug Conjugates Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 12.05 Billion |
Market Size (2029) | USD 44.05 Billion |
CAGR (2024 - 2029) | 29.57 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Antibody Drug Conjugates Market Analysis
The Antibody Drug Conjugates Market size is estimated at USD 12.05 billion in 2024, and is expected to reach USD 44.05 billion by 2029, growing at a CAGR of 29.57% during the forecast period (2024-2029).
The COVID-19 pandemic had a notable impact on the antibody drug conjugate market since many cancer consultations and treatments were postponed or canceled due to the lockdown restrictions. For instance, according to the National Health Service (NHS) of the United Kingdom, in 2023, there was a shortfall in cancer treatments during the pandemic, driven by a sharp drop in urgent referrals as people needed the stay-at-home due to the lockdown restrictions, which significantly reduced the demand for overall cancer therapies including antibody drug conjugate (ADC).
Moreover, according to the Annual Report 2022 of Seagen Inc., a leading manufacturer of antibody drug conjugate (ADC), the COVID-19 pandemic had adverse impacts on the ADC companies business, including commercialization efforts, supply chain, regulatory activities, clinical development activities, and others. Thus, the COVID-19 pandemic significantly impacted the business operations of ADC manufacturing companies, thus impacting the sale of antibody drug conjugate. However, the increasing approvals and launches of antibody drug conjugate in the post-pandemic period attain growth in the market over the coming years.
The major factors responsible for the growth of the ADC market include the growing prevalence of cancer, the increasing geriatric population, and increasing R&D activities for the development of novel therapeutics. Antibody drug conjugates offer one of the most effective treatments for cancer patients. They can exploit the specificity of monoclonal antibodies toward targeted antigens for the release of potential cytotoxic drugs, with increased activity and decreased toxicity as compared to chemotherapies.
The rising incidence of cancer in various countries increases the usage of ADC for treatment. For instance, according to the May 2022 update by the Canadian Cancer Society, 28,600 Canadian women were diagnosed with breast cancer in 2022, representing 25% of all new cancer cases in women in 2022. Also, on average, 78 Canadian women were expected to be diagnosed with breast cancer daily in 2022. Thus, owing to the high prevalence and increase in the probability of acquiring breast cancer among females, the demand for antibody drug conjugates is likely to rise, fueling the market growth over the forecast period.
The increasing investments in the ADC market are expected to boost the antibody drug conjugate pipeline and expand its applications, which may positively impact the market's growth. For instance, in June 2022, Spirea Limited secured funding of GBP 2.4 (USD 3.06) million with investments from high-profile investors from the United Kingdom and the United States. The company uses these funds to initiate its pipeline of superior and differentiated ADC in the treatment of solid tumors, thereby contributing to the growth of the market.
However, the stringent government regulations and high manufacturing costs of antibody drug conjugate are expected to restrain the market's growth over the forecast period.
Antibody Drug Conjugates Industry Segmentation
Antibody drug conjugates are a class of biopharmaceuticals designed for the treatment of cancer, comprising an antibody that specifically targets a tumor antigen and a cytotoxic compound connected via a chemical linker. These are intended to allow the specific targeting of the cytotoxic compound to kill cancer cells while having a limited effect on healthy tissue.
The antibody drug conjugates market is segmented by product type (adcetris, kadcyla, and other product types), application (blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, brain tumor, and other applications), technology (cleavable linker and non-cleavable linker), target type (CD30 antibodies, HER2 antibodies, and other target types), end user (hospitals and specialty cancer centers, biotechnology and pharmaceutical companies, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated antibody drug conjugates market sizes and trends for 17 countries across major regions globally.
The report offers the value in USD for the above segments.
By Product Type | |
Adcetris | |
Kadcyla | |
Other Product Types |
By Application | |
Blood Cancer | |
Breast Cancer | |
Ovary Cancer | |
Lung Cancer | |
Skin Cancer | |
Brain Tumor | |
Other Applications |
By Technology | |
Clevable Linker | |
Non-cleavable Linker |
By Target Type | |
CD30 Antibodies | |
HER2 Antibodies | |
Other Target Types |
By End User | |
Hospitals and Speciality Cancer Centers | |
Biotechnology and Pharmaceutical Companies | |
Other End Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Antibody Drug Conjugates Market Size Summary
The antibody drug conjugates (ADC) market is poised for substantial growth, driven by the increasing prevalence of cancer and the rising geriatric population. ADCs are gaining traction as effective cancer treatments due to their ability to deliver cytotoxic drugs directly to cancer cells, minimizing toxicity compared to traditional chemotherapies. The market is experiencing a resurgence post-COVID-19, which had previously disrupted cancer treatments and ADC business operations. The pandemic's impact on supply chains, regulatory activities, and clinical development has been significant, but the subsequent approvals and launches of ADCs are expected to propel market expansion. The market's growth is further supported by heightened research and development activities aimed at developing novel therapeutics, alongside increasing investments that are expected to enhance the ADC pipeline and broaden its applications.
North America is anticipated to be a key region for market growth, fueled by technological advancements and a high incidence of cancer cases. The presence of major players and strategic initiatives in the United States and Canada are contributing to the region's expansion. The competitive landscape of the ADC market is characterized by the presence of several global and local companies, with key players like Seagen Inc., ImmunoGen Inc., and Pfizer Inc. holding significant market shares. Partnerships and new product approvals are pivotal in driving market growth, as evidenced by recent collaborations and licensing agreements. Despite the market's potential, challenges such as stringent government regulations and high manufacturing costs may pose constraints. Nonetheless, the ongoing development and approval of ADCs, particularly for breast cancer treatment, are expected to sustain the market's upward trajectory over the forecast period.
Antibody Drug Conjugates Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidences of Cancer
-
1.2.2 Growing Geriatic Population
-
1.2.3 Increasing R&D Activities for the Development of Novel Therapeutics
-
-
1.3 Market Restraints
-
1.3.1 Stringent Government Regulations
-
1.3.2 High Manufacturing Costs of Antibody Drug Conjugates
-
-
1.4 Industry Attractiveness - Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Buyers/Consumers
-
1.4.2 Bargaining Power of Suppliers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Product Type
-
2.1.1 Adcetris
-
2.1.2 Kadcyla
-
2.1.3 Other Product Types
-
-
2.2 By Application
-
2.2.1 Blood Cancer
-
2.2.2 Breast Cancer
-
2.2.3 Ovary Cancer
-
2.2.4 Lung Cancer
-
2.2.5 Skin Cancer
-
2.2.6 Brain Tumor
-
2.2.7 Other Applications
-
-
2.3 By Technology
-
2.3.1 Clevable Linker
-
2.3.2 Non-cleavable Linker
-
-
2.4 By Target Type
-
2.4.1 CD30 Antibodies
-
2.4.2 HER2 Antibodies
-
2.4.3 Other Target Types
-
-
2.5 By End User
-
2.5.1 Hospitals and Speciality Cancer Centers
-
2.5.2 Biotechnology and Pharmaceutical Companies
-
2.5.3 Other End Users
-
-
2.6 Geography
-
2.6.1 North America
-
2.6.1.1 United States
-
2.6.1.2 Canada
-
2.6.1.3 Mexico
-
-
2.6.2 Europe
-
2.6.2.1 Germany
-
2.6.2.2 United Kingdom
-
2.6.2.3 France
-
2.6.2.4 Italy
-
2.6.2.5 Spain
-
2.6.2.6 Rest of Europe
-
-
2.6.3 Asia-Pacific
-
2.6.3.1 China
-
2.6.3.2 Japan
-
2.6.3.3 India
-
2.6.3.4 Australia
-
2.6.3.5 South Korea
-
2.6.3.6 Rest of Asia-Pacific
-
-
2.6.4 Middle East and Africa
-
2.6.4.1 GCC
-
2.6.4.2 South Africa
-
2.6.4.3 Rest of Middle East and Africa
-
-
2.6.5 South America
-
2.6.5.1 Brazil
-
2.6.5.2 Argentina
-
2.6.5.3 Rest of South America
-
-
-
Antibody Drug Conjugates Market Size FAQs
How big is the Antibody-drug Conjugates Market?
The Antibody-drug Conjugates Market size is expected to reach USD 12.05 billion in 2024 and grow at a CAGR of 29.57% to reach USD 44.05 billion by 2029.
What is the current Antibody-drug Conjugates Market size?
In 2024, the Antibody-drug Conjugates Market size is expected to reach USD 12.05 billion.